Our findings demonstrated that KIRA8 treatment suppressed the transition to the G2/M phase in myeloma cells, followed by the PLK2-dominant inhibitor exhibiting a similar effect as KIRA8. This evidence concerns the gene PLK2 and plasma cell myeloma.